Journal of Clinical Medicine · 10 authors, 7 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This systematic review followed PRISMA guidelines and searched Ovid Medline, Embase, Cochrane Register of Controlled Trials, and Cochrane Database of Systematic Reviews from inception to 14 June 2022, identifying 81 eligible articles from 2745 initially extracted.
This systematic review followed PRISMA guidelines and searched Ovid Medline, Embase, Cochrane Register of Controlled Trials, and Cochrane Database of Systematic Reviews from inception to 14 June 2022, identifying 81 eligible articles from 2745 initially extracted. Studies were assessed for evidence quality using the GRADE system. Treatment modalities reviewed included intravitreal anti-VEGF monotherapy, pneumatic displacement with expansile gas, vitrectomy with or without subretinal rt-PA injection, and photodynamic therapy. The authors noted that the number of prospective trials specifically targeting SRMH is limited, with most evidence derived from retrospective studies and small sample sizes. While various treatments showed encouraging results, none was established as definitively superior. Timing of intervention and hemorrhage size were identified as important prognostic factors. The review concluded that further robust prospective research is needed to guide evidence-based treatment selection.
